A long-acting injection developed by GlaxoSmithKline <GSK.L> and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker’s key HIV business.
GSK’s majority-owned ViiV Healthcare unit said on Wednesday the experimental two-drug injection of cabotegravir and rilpivirine maintained similar rates of viral suppression compared with a standard three-drug oral regimen, after 48 weeks of a clinical trial.
The result is a boost for GSK’s goal of developing two-drug HIV treatments that are easier to tolerate than conventional triple-drug therapies. If follows recent positive data from combining two oral drugs.
GSK hopes its new approach will allow it to compete more effectively against Gilead Sciences, the US drugmaker that currently dominates the HIV market.
Published in Daily Times, August 16th 2018.
The Supreme Court's Justice Mansoor Ali Shah on Saturday said that developing a firewall around…
Got the bat. Lost the bat. Got it again. Lost it again. No intra-party polls…
Prime Minister Shehbaz Sharif on Saturday arrived in Riyadh, Saudi Arabia, to participate in a…
Skipper Babar Azam hit a solid half century while spearhead Shaheen Shah Afridi grabbed four…
The Supreme Court on Saturday directed the authorities concerned to remove all encroachments across the…
The Pakistan Electronic Media Regulatory Authority (PEMRA), Pakistan Telecommunication Authority (PTA), Federal Investigation Agency (FIA),…
Leave a Comment